ENGLEWOOD, Colo., May 12, 2025 - Zynex, Inc. $(ZYXI)$, a leader in medical technology, has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its NiCO™ Noninvasive CO-Oximeter device. This submission is a significant step in the company's efforts to innovate within the field of patient monitoring. The NiCO Laser Pulse Oximeter is designed to provide more reliable and accurate oxygen status information, potentially revolutionizing the pulse oximetry market, which is projected to grow from $2.8 billion today to $4.3 billion by 2027. The device aims to enhance patient care by offering real-time data on various hemoglobin species, enabling earlier detection of conditions such as hypoxia and hyperoxia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.